COR2ED - Oncology Medical Conversation Video

COR2ED Medical Education
  • 0.0 (0)
  • SCIENCE
  • UPDATED MONTHLY
COR2ED - Oncology Medical Conversation Video

Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com

  1. JAN 20 · VIDEO

    Intermediate HCC – The evolving role of IO

    Intermediate HCC – The evolving role of IO  In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.   Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways. They delve into the latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, discussing clinical implications. The conversation also underscores the importance of effective collaboration within the multidisciplinary team for delivering optimal patient care. The episode concludes with future perspectives in the field and key clinical takeaways on integrating IO with loco-regional therapy and the significance of multidisciplinary care in managing HCC.  Key clinical takeaways:   IO and IO-based treatments are moving earlier in the treatment paradigm for patients with intermediate HCC. Earlier integration of these therapies aims to achieve improved systemic control, allowing loco-regional therapy to target oligoprogression, residual lesions or reduce tumour burden    Emerging data supports combining systemic and loco-regional therapies for patients with intermediate HCC. EMERALD-1 and LEAP-012 show promising PFS data using IO-based combination regimens like durvalumab + bevacizumab or pembrolizumab + lenvatinib alongside TACE. Long-term OS data are awaited    Effective communication and coordinated care among specialists, such as medical oncologists, radiation oncologists, hepatologists, and interventional radiologists, are essential to developing optimal treatment strategies for patients with intermediate HCC      You can also watch a video of the experts in conversation and download the accompanying slides and transcript on our website: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-the-evolving-role-of-io/  Or watch on YouTube: https://www.youtube.com/watch?v=3voWa0U96lE    Follow us on social media:  LinkedIn: https://www.linkedin.com/company/hcc-connect/ X https://x.com/hccconnectinfo     This content is intended for healthcare professionals only.   The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.  This podcast is developed by cor2ed.com  Published on January 2025  Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. ...

    27 min

  2. JAN 7 · VIDEO

    Intermediate HCC – treatment options and strategies

    In the third of this 4-part podcast series on HCC, the Oncology Brothers Dr Rahul and Dr Rohit Gosain are joined by Hepatologist Dr Maria Reig and Interventional Radiologist Dr Emil Cohen to explore the complexities of managing intermediate-stage hepatocellular carcinoma (HCC). Together, they unpack treatment options and strategies through a dynamic and engaging discussion rooted in real-world clinical practice.  Key topics include:  An overview of the available treatment options for this heterogeneous patient population with intermediate HCC  A deep dive into loco-regional therapies, including TACE, TARE (Y-90), and SBRT  Exploring the role of systemic treatments in patients with intermediate HCC and the use of multimodal treatment approaches, combining loco-regional treatment options with systemic treatments  The importance of the multidisciplinary care team for the treatment of intermediate HCC    Key clinical takeaways:   Defined by guidelines, treatment options for patients with intermediate HCC include liver transplantation, loco-regional therapies, and systemic therapy. Treatment selection depends not only on tumour burden and liver function, but also on practical considerations in clinical practice  Systemic therapies are being evaluated earlier in the disease course, particularly for intermediate HCC, either as standalone treatments or in combination with loco-regional therapies  Ongoing clinical trials, such as REPLACE and ABC-HCC, aim to clarify the role of systemic therapies in intermediate HCC as standalone options, while others, like EMERALD-1 and LEAP-012, focus on their use in combination with loco-regional approaches  Adverse events require identification of the specific adverse events profile. Regardless of origin (systemic or loco-regional), complications must be resolved to maintain treatment efficacy and ensure patient safety  Optimal care for intermediate HCC relies on a multi-disciplinary team, including hepatologists, interventional radiologists, radiation oncologists, surgeons, and medical oncologists      Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/     Follow us on social media:  LinkedIn: https://www.linkedin.com/company/hcc-connect   X: https://x.com/hccconnectinfo     This content is intended for healthcare professionals only.   The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.    This podcast is developed by cor2ed.com  Published January 2024    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

    20 min

  3. 12/03/2024 · VIDEO

    HCC podcast series part 2: 2nd line treatment in advanced HCC and when to switch

    Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dives into 2nd line treatment selection in advanced HCC and the key considerations for deciding when to switch therapies.    Topics include:  2nd line options for advanced HCC after 1st line TKIs and IO-based therapies  Sequencing strategies and clinical practice approaches  Key data supporting 2nd line decisions  Factors to consider when transitioning to 2nd line therapy    Key clinical takeaways:   Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions  When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life.  Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered  Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management  Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation      Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/     Follow us on social media:  LinkedIn: https://www.linkedin.com/company/hcc-connect   X: https://x.com/hccconnectinfo     This content is intended for healthcare professionals only.   The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.    This podcast is developed by cor2ed.com  Published December 2024    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

    26 min

  4. 11/25/2024 · VIDEO

    Testing to treatment of BRAF-mutant metastatic NSCLC

    Testing to treatment of BRAF-mutant metastatic NSCLC    In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.   The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients.  Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment.   The experts also discuss how to treat patients who have co-mutations detected during testing.  This is an informative podcast that culminates in some interesting key messages from two well-recognised Experts in the field of NSCLC.      Key clinical takeaways:   Test all patients irrespective of histology and smoking history  Test upfront so that more efficacious agents can be used earlier in the patient journey  Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed  There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles    Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/UZPBUAFOwcY Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/   Follow us on social media:  LinkedIn: https://www.linkedin.com/company/lungconnect/   X: https://x.com/lung_connect     This content is intended for healthcare professionals outside of the UK & ROI only.   The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This podcast is developed by https://cor2ed.com/  Published November 2024    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

    23 min

  5. 11/21/2024 · VIDEO

    HCC podcast series part 1: The use of IO in unresectable HCC

    In the first of this 4-part podcast series on HCC, Dr Rachna Shroff and Oncology Brothers Drs Rohit and Rahul Gosain explore the use of IO (immunotherapy) in unresectable HCC (uHCC) and take a deep dive into the different treatment options first-line focusing on IO and IO based combinations. Topics include:    Current first-line systemic treatment options for uHCC  Efficacy and safety of IO and IO combinations including practical aspects of identifying and managing immune-mediated AEs  How to select between the two first-line IO-based treatment options based on clinical factors and practical considerations     Key clinical takeaways: Two first-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape  Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies  Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen ( single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up  IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary.  In clinical practice, treatment choice should be individualized, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits      Follow us on social media:  LinkedIn: https://www.linkedin.com/company/hcc-connect   X: https://x.com/hccconnectinfo     This content is intended for healthcare professionals only.   The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme.    This podcast is developed by cor2ed.com  Published on November 2024    Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

    23 min

  6. 11/08/2024 · VIDEO

    BRAF-mutated CRC: testing to treatment

    Experts Prof. Sebastian Stintzing and Dr Thomas Winder discuss the significance of BRAF mutations in colorectal cancer (CRC), and the testing strategies and available treatments for these patients.     They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.     Several key trials are discussed, including the BEACON trial which resulted in encorafenib plus cetuximab being the standard of care in the second-line setting for patients with BRAF mutated CRC.     The discussion also looks at future studies including the BREAKWATER trial, which will provide important information about encorafenib plus cetuximab in the first-line for these patients, as well as the SEAMARK trial which will show the effects of adding immunotherapy to this combination.      Key clinical takeaways:  BRAF mutations occur in around 10% of colorectal cancer patients and patients harbouring these have aggressive disease and a poor prognosis  Targeted therapies are available for BRAF-mutated CRC so it is important to test patients early in their disease preferably with next-generation sequencing  Encorafenib plus cetuximab are established as the standard of care in the second-line setting for BRAF-mutated CRC  Doublet chemotherapy plus anti-VEGF is currently the preferred treatment in the first-line. The BREAKWATER trial will determine whether the combination of encorafenib plus cetuximab is a suitable first-line treatment option    Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/Pp7oAI9JW4A  Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/gi-connect/programmes/braf-mutated-crc-testing-treatment/    Follow us on social media:  LinkedIn: https://www.linkedin.com/company/giconnect    X: https://x.com/giconnectInfo     This content is intended for healthcare professionals outside of the UK & ROI only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This podcast was developed by https://cor2ed.com/   Published November 2024

    26 min

  7. 09/11/2024 · VIDEO

    Neuroendocrine tumours (NETs) – Shared decision-making. Part 2: Individualising treatment decisions

    In this second episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins explore shared decision-making, between patient and physician.     The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions.    Prefer to watch and listen? Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/?media=1  Watch the full video on YouTube https://youtu.be/2JYuPhc2jHg  Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k     Follow us on social media  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect   X: https://x.com/net_connectinfo     This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Medical Education Grant from Ipsen  This podcast is developed by cor2ed.com  Published July 2024

    23 min

  8. 09/11/2024 · VIDEO

    Neuroendocrine tumours (NETs) – Shared decision-making. Part 1: Patient journey

    In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins discuss the importance of communication and collaboration during consultations. This can include how to make a patient feel as comfortable and in control as possible, as well as recognising their goals and concerns.     The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET treatment options in daily life.     NETs are complex, rare diseases. Optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. Are you aware of how healthcare practitioners and patients can share decision- making? Or the recent data on how patients prefer to receive treatment?     In this first episode of a two-part podcast series, Dr Mohid S Khan and NET patient Sally Jenkins discuss shared decision-making in NET consultations and ways to help the patient in their journey.    Prefer to watch and listen? Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/ Watch the full video on YouTube https://youtu.be/YgqrEnSePWg Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k   Follow us on social media  LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect   X: https://x.com/net_connectinfo     This content is intended for healthcare professionals only.  The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen  This podcast is developed by cor2ed.com  Published July 2024

    30 min
See All (25)

About

Join oncology experts as they discuss their approaches to diagnosing and managing patients with gastrointestinal, genitourinary, lung, breast, gynecological, neuroendocrine and hematological cancers, sarcomas, and more. The conversations also explore cutting edge developments in precision oncology, as well as emerging treatments, including immunotherapy. This independent medical education podcast is for HCPs with the ultimate goal of improving care for their patients. For more information, visit www.cor2ed.com

Information

To listen to explicit episodes, sign in.

Stay up to date with this show

Sign in or sign up to follow shows, save episodes, and get the latest updates.
Select a country or region

Africa, Middle East, and India

Asia Pacific

Europe

Latin America and the Caribbean

The United States and Canada